T A B L E O F C O N T E N T S
The six-dose regimen of artemether-lumefantrine appears more effective than antimalarial regimens not containing artemisinin derivatives.
P L A I N L A N G U A G E S U M M A R Y

Artemether-lumefantrine (six-dose regimen) for treating uncomplicated malaria
Malaria is a parasitic disease, spread by mosquitoes. It affects millions of people worldwide, and causes significant illness and mortality. Uncomplicated malaria presents with symptoms such as fever, headache, muscle pain, and vomiting. The parasite has become resistant to a number of previously effective drugs, and so combinations of drugs are used to try increase cure and to prevent further resistance. Artemether-lumefantrine is one such drug combination. This review of trials showed that the six-dose regimen of artemether-lumefantrine was associated with high cure rates and was more effective that most other drug combinations used for uncomplicated malaria. Further research is needed to properly assess adverse outcomes.
B A C K G R O U N D Malaria
Malaria is a major health problem with at least 300 to 500 million people diagnosed with the illness every year (WHO 2000a) . The main cause is Plasmodium falciparum, one of the four species of malaria parasites found in humans. Uncomplicated malaria occurs in the majority of those affected, and is the form of the illness which presents with such symptoms as fever, headache, muscle pain (myalgia), vomiting, mild diarrhoea, anaemia, and enlarged spleen (splenomegaly). In addition, children commonly present with rapid breathing (tachypnoea), cough, and convulsions.
Antimalarial drug resistance
Resistance to antimalarial drugs emerged in South-East Asia and South America (White 1999a), and then spread to Africa and western Oceania. Sulfadoxine-pyrimethamine has replaced chloroquine as the first-line treatment in some African countries (such as Malawi and Kenya), but resistance to this is now also emerging (WHO 2000a) . Resistance to sulfadoxine-pyrimethamine is relatively common in South-East Asia (WHO 2001b) , where resistance and declining sensitivity to mefloquine have also been reported (WHO 2000a) . Mefloquine is contraindicated in areas of intensive malaria transmission, such as sub-Saharan Africa, because its long half life may expose parasites to subcurative doses, which could result in the development of resistant strains (WHO 2000a) . Artemisinin drugs, including artemether and artesunate, are now used as first-line treatment in some countries in South-East Asia, but they are recommended only as combination treatment (WHO 2000a) . Such combination therapy affords rapid clinical response and higher cure rates when compared with other antimalarial combinations (White 1999a) . It is also thought combination therapy may slow the parasite developing resistance to the drug (White 1999b).
Artemether-lumefantrine combination
The fixed-dose combination of artemether-lumefantrine, called co-artemether, contains 20 mg of artemether and 120 mg of lumefantrine (previously called benflumetol). It was initially developed by scientists at the Academy of Military Medical Sciences in China before the pharmaceutical company Novartis (Switzerland) became a partner and was licensed to market it as Coartem® or Riamet®. This oral preparation has been designed for use against chloroquine-resistant falciparum malaria. Artemether has a rapid onset of action and is rapidly eliminated from the plasma (half life of two to three hours; Lefèvre 1999). Lumefantrine is cleared more slowly and has a longer elimination half life (approximately 4.5 days; Ezzet 1998). The rationale behind this combination is that artemether initially provides rapid symptomatic relief by reducing the number of parasites present before lumefantrine elimi-nates any residual parasites. This is thought to minimize development of resistance because the malaria parasites are never exposed to artemether alone (due to its rapid elimination). Although they may be exposed to lumefantrine alone, the probability of resistance developing simultaneously to both drugs used in combination is thought to be low (Bloland 2000) . Artemether-lumefantrine also reduces gametocyte carriage and thus should have an impact on malaria transmission (Van Vugt 1998a). There has been some concern about the possible risk of neurotoxicity with artemisinin derivatives that arose from animal studies using high doses of lipid-soluble preparations given intramuscularly (WHO 1999) . No serious adverse or persistent neurotoxic adverse events have been documented (Novartis 2005) . There has been concern that the lumefantrine component could have adverse cardiac effects due to its similar structure to halofantrine (Bindschedler 2000) . Artemether-lumefantrine causes minimal QTc prolongation which was not associated with adverse clinical cardiac events (Novartis 2005). These potential adverse effects have to be considered when assessing the drug combination. Artemether-lumefantrine has been added to the WHO Model list of Essential Medicines and is being promoted in Africa as firstline treatment for malaria by the World Health Organization. The World Health Organization has commended the company for providing the drug at discounted prices for developing countries in malaria endemic areas ( WHO 2001a).
Rationale for review
Since the first Cochrane Review on artemether-lumefantrine was published (Omari 2002), the six-dose regimen has become the standard, as researchers acknowledged the review findings that the four-dose regimen was associated with treatment failures (Nosten 2003) . Trials are generally using the six-dose regimen, with the evidence for the four-dose regimen maintained in a separate Cochrane Review (Omari 2006) . This review aims to summarize the existing evidence of the six-dose regimen of artemether-lumefantrine and how it compares with other antimalarial drugs for treating uncomplicated falciparum malaria, including mefloquine, sulfadoxinepyrimethamine, and chloroquine. For our endpoint, we use total failure by day 28 as the primary outcome measure, or day 42 for sulfadoxine-pyrimethamine and day 63 for mefloquine because of their long half lives. In areas where malaria transmission is intense, recurrence of parasites by day 28 could also be due to reinfection, so we also examine the polymerase chain reaction (PCR) which is thought to distinguish between a new infection and recurrence of malaria (recrudescence) due to drug resistance.
O B J E C T I V E S
To evaluate the six-dose regimen of artemether-lumefantrine for treating uncomplicated falciparum malaria.
M E T H O D S
Criteria for considering studies for this review
Types of studies
• Randomized controlled trials.
Types of participants
• Adults and children with acute uncomplicated malaria, as defined in WHO 2000b, with asexual P. falciparum parasitaemia confirmed using blood slides.
Types of interventions
• Six doses of artemether-lumefantrine administered orally versus standard treatment regimens (single drugs or combinations).
• Supervised versus unsupervised treatment with the six doses of artemether-lumefantrine.
Types of outcome measures
Primary
• Total failure by day 28, day 42 (for sulfadoxinepyrimethamine), or day 63 (for mefloquine); defined as a recurrent malaria infection with or without clinical malaria.
Secondary
• Total failure, defined as a recurrent malaria infection with or without clinical malaria, by day 7.
• Total failure, defined as a recurrent malaria infection with or without clinical malaria, by day 14.
• Total failure adjusted by PCR to exclude new infections by day 28 (recrudescent infections).
• Parasite clearance time (PCT), defined as the time between commencing treatment and the first negative blood test when negativity persists for more than 48 hours; PCT 50, defined as the time taken for parasites to be reduced to 50% of first test value; and PCT 90, defined as the time taken for parasites to be reduced to 10% of first test value.
• Fever clearance time, defined as the time between commencing treatment and the temperature returning to normal and remaining normal for more than 48 hours.
• Gametocyte carriage on days 14 and 28.
• Gametocyte clearance time, defined as the time taken for gametocytes to disappear (if present in the blood initially) after commencing treatment.
Adverse events
• Adverse events requiring discontinuation of treatment, or are fatal, life-threatening, or requiring hospitalization.
• Other adverse events.
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press , and in progress).
Databases
We searched the following databases using the search terms and strategy described in 
Researchers, organizations, and pharmaceutical companies
We contacted researchers working in the field, the World Health Organization, and the pharmaceutical company Novartis for unpublished and ongoing trials.
Data collection and analysis
Selection of studies
Aika Omari (AO) screened the results of the search strategy to identify potentially relevant trials. AO and Carrol Gamble (CG) independently assessed the eligibility of these trials for inclusion in the review using the stated inclusion criteria. Any differences in opinion between the authors were discussed with the third author Paul Garner.
Data extraction and management
AO and CG independently extracted data of trial characteristics including methods, participants, interventions, and outcomes, and recorded the data on standard forms. Where data from the published papers were insufficient or missing, we contacted the trial authors for additional information. Where possible, we extracted data to allow an intention-to-treat analysis (the analysis should include all the participants in the groups to which they were originally randomly assigned). If the number randomized and the numbers analysed were inconsistent, we calculated the percentage loss to follow up. For dichotomous outcomes, we recorded the number of participants experiencing the event in each group of the trial. For continuous outcomes, we extracted arithmetic means and standard deviations and combined means using mean difference for each group where possible. If the data were reported using geometric means, we extracted standard deviations on the log scale, and extracted and reported the medians and ranges.
Assessment of risk of bias in included studies
We assessed of the generation of allocation sequence and concealment of allocation as adequate, inadequate, or unclear according to Jüni 2001. We described who was blinded to the interventions, such as the participants, care providers, or outcome assessors. We assessed the inclusion of all randomized participants in the main effectiveness analysis to be adequate if more than 90% were included in the analysis, inadequate if 90% or less, or unclear.
Data synthesis
We compared the drug with non-artemisinin derivative regimens, other artemisinin regimens, and then other comparisons that examined delivery. Adverse events from all trials were reported together. We analysed data using Review Manager 5. We compared outcome measures for dichotomous data using risk ratio (RR), which is the risk of achieving an outcome in the artemether-lumefantrine group relative to that in the control group. We used total failure (clinical or parasitological failure by day 28) as our main outcome, and we also conducted analysis excluding reinfection where PCR data were available. As the value of the risk ratio is constrained to lie between 0 and 1/CGER (control group event rate), large values of the risk ratio are impossible when events are common, so failure is preferred to treatment success. We would consider the DerSimonian Laird random-effects model if there was significant heterogeneity.
We intend to explore the following potential sources of heterogeneity using subgroup analyses or meta-regression: participant age (under five years versus five years or more); trial setting (high malaria transmission versus low transmission); and the presence of drug resistance to comparator drug, as new trials become available. Additional trials may allow sensitivity analyses according to blinding, allocation concealment, and whether the trials used an intention-to-treat analysis at a future date. In determining the effectiveness of antimalarial treatment, we intended to extract the results of analyses conducted according to the intention-to-treat principle. This approach is considered to be more pragmatic as it attempts to estimate the effectiveness of the treatment in routine practice rather than in the context of a clinical trial. To allow the intention-to-treat principle to be applied, all participants should be followed for the duration of the trial irrespective of whether or not the treatment course was completed or other protocol deviations. Any reason for dropping out of the trial or being excluded from the trial should be documented (WHO 1996) . For total failure with trials that had conducted PCR analysis, we classified the infections into: recrudescent infection (matching genotypes on day 0 and day of recurrence); new infection (different genotypes on day 0 and day of recurrence); and missing values. We intended to conduct a sensitivity analysis around PCR examining the effect of missing data, but there were too few trials for us to do this.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies. We identified 31 potentially relevant studies. Nine met the inclusion criteria (see 'Characteristics of included studies'); one trial was reported across two publications (Van Vugt 2000). We excluded 16 studies, including one reported in two separate publications (Hatz 1998), for the reasons given in the 'Characteristics of excluded studies'. We have requested data since 2003 on four studies from Novartis (cited in Novartis 1999), but have not yet received a response. 
Trial location
Dose and regimen
All trials administered the six doses over 72 hours. Children received between 3.8 and 16 mg/kg of artemether and between 48 and 96 mg/kg of lumefantrine; adults received 480 mg of artemether and 2280 mg of lumefantrine.
Antimalarial drug resistance
Chloroquine resistance and sulfadoxine-pyrimethamine resistance were reported in trials conducted in Tanzania, Burundi, The Gambia, Uganda, and Lao PDR. Multiple-drug resistance was reported in Thailand.
Outcome measures
(See Appendix 2). Total failure (illness with parasitaemia or parasitaemia detected by day 28) was the most frequently reported outcome (six of the nine trials). Two trials reported failure by day 42 (Mayxay 2004; Stohrer 2004) . Trials also reported the number of treatment failures at other time points (days one, two, three, seven, and 14). Fever clearance was reported in three trials, and time to parasite clearance was reported in three trials. Gametocyte carriage was reported in eight trials and gametocyte clearance in two trials. Polymerase chain reaction (PCR) analysis was reported in seven trials, and all trials reported adverse events.
Risk of bias in included studies
See Table 1 for the assessment and the 'Characteristics of included studies' for details. a Inclusion of all randomized participants in the analysis; see the 'Methods of the review' for the assessment methods, and the ' Characteristics of included studies' for the methods used in each trial.
Generation of allocation sequence
All the trials were reported as randomized. Two trials reported using an adequate method to generate the allocation sequence. The remaining seven trials mentioned randomization, but they did not report how they generated the allocation sequence.
Concealment of allocation
Allocation concealment was adequate in the six trials that used central randomization, or numbered, sealed, opaque envelopes. The other three trials did not describe the method used to conceal allocation.
Blinding
One trial was single blind in which all staff apart from those in recruiting clinic and field assistants were not aware of the treatment group. The remaining eight trials were described as open.
Inclusion of randomized participants in the analysis
None of the nine trials had complete data for all participants randomized into the trial for the duration of follow up. This was partly because researchers stopped follow up after a participant withdrew. Therefore an intention-to-treat analysis was not possible for the trial investigators or for this review because data necessary for an intention-to-treat analysis were not collected. All trials gave results of analyses based on evaluable participants, that is, participants still on treatment at each time point. Three of the trials, however, also claimed to have reported cure rates as an 'intention-to-treat' analysis (Lefevre 2001; Mayxay 2004; Sutherland 2005) These are not the results of an intention-to-treat analysis, and differed from their evaluable participants analysis by assuming that all participants withdrawn from treatment or lost to follow up still had parasitaemia at all remaining time points. At the end of follow up, the number of participants evaluable for the primary outcome was greater than 90% in six trials and 85% to 90% in three trials . 
Dihydroartemisinin-napthoquine-trimethoprim (DNP) (130 participants, 1 trial)
Krudsood 2003, which was conducted in Thailand, reported equal numbers of parasitological failures in both groups on day 28 (RR 2.35, 95% CI 0.15 to 36.54, Analysis 6.1). This result was not statistically significant, but it is imprecise due to the wide confidence interval. The trial authors reported no statistically significant difference (P = 0.18) between the groups in the mean parasite clearance times for artemether-lumefantrine (48.1 h; 34 participants) compared with DNP (43.0 h; 80 participants) (Appendix 3). This was also the case for the mean fever clearance times (P = 0.35): 41.2 hours (34 participants) for artemether-lumefantrine compared with 32.8 hours (80 participants) for DNP (Appendix 4).
Supervised versus unsupervised treatment (957 participants, 1 trial)
Piola 2005, conducted in Uganda, compared supervised with unsupervised treatment with artemether-lumefantrine. There was no statistically significant difference in the number of total failures by day 28 between the groups (RR 1.18, 95% CI 0.47 to 2.98; 918 participants, Analysis 7.1).
Adverse events
All nine trials reported adverse events. The majority of adverse events reported were mild or moderate (Appendix 8), although some were severe (Appendix 9). One trial published adverse cardiac events separately and reported no clinically significant changes in the electrocardiographic intervals (Van Vugt 2000). One trial reported cardiac monitoring (Lefevre 2001), and one reported no difference in the QTc interval (difference between the longest and shortest measurable interval on the 12 lead electrocardiogram, corrected for heart rate) between treatment groups (Lefevre 2001).
D I S C U S S I O N Trial methods
The risk of bias in several of the included trials was below average given current standards. Seven of the nine trials did not describe the method used to generate the allocation sequence and three did not describe how allocation was concealed. In seven trials, 90% or more of the participants were included in the final analysis for the reported primary outcome. The 'intention-to-treat' analysis for the primary outcome reported in five trials was actually a limited form of sensitivity analysis because they made the assumption that all participants lost to follow up were treatment failures. As results were not based on an intention-to-treat analysis, they are subject to attrition bias and the clinical effectiveness may be biased.
PCR analysis
Data for failure by day 14 and day 28 were corrected for new infections with missing samples or failed tests classified as treatment failures. This had a minimal effect for mefloquine plus artesunate and the result remained statistically insignificant in favour of mefloquine artesunate. Although PCR results were reported in seven trials, results from different groups were combined making it difficult to draw any valid conclusions and PCR data were not reported on all treatment failures.
Non-artemisinin therapies
The results of a Cochrane Review of the four-dose regimen showed that it was often less effective than other standard treatment regimens (Omari 2006). The review included a trial comparing fourdose and six-dose regimens, and the six-dose regimen had fewer treatment failures, and this was statistically significant. The six-dose regimen of artemether-lumefantrine performed better than amodiaquine and amodiaquine plus sulfadoxine-pyrimethamine. Total failure was lower with artemetherlumefantrine compared with chloroquine plus sulfadoxinepyrimethamine in two trials, but this was not statistically significant. Background resistance to chloroquine and sulfadoxinepyrimethamine in both trial areas could have affected the performance of the non-artemisinin combination. One of the trials, Sutherland 2005, did not report outcomes on day 42, which would have been more informative due to the long half life of sulfadoxine-pyrimethamine. Parasite and fever clearance times were shorter for artemetherlumefantrine when compared with chloroquine plus sulfadoxinepyrimethamine, which suggests that clinical symptoms may resolve faster.
Artemisinin combination therapies
In comparisons with other artemisinin-combination therapies, fewer participants failed treatment with artemether-lumefantrine compared with amodiaquine plus artesunate. However, the combination of mefloquine and artesunate was more effective at reducing parasitological failure on days 28 and 42. None of the trials reported outcomes on day 63 despite the long half life of mefloquine. There was no difference in parasitological failures between artemether-lumefantrine and dihydroartemisinin-napthoquine-trimethoprim, but the trial may have been too small (130 participants) to detect any statistically significant difference. There was no difference in the parasite, fever, and gametocyte clearance times in comparisons with mefloquine plus artesunate and dihydroartemisinin-napthoquine-trimethoprim. This is not surprising due to the artemisinin component in both therapies.
Supervised versus unsupervised treatment
Artemether-lumefantrine given without supervision (which is normal clinical practice) showed no difference in the failure rate compared with supervised delivery.
Clearance times
Trials reported clearance times as medians, percentiles, and means. It would have been more informative reporting these as time-toevent analyses, as data on participants who did not reach the event would have been included in the analysis.
Adverse events
In some trials where adverse events were reported, no distinction was made between the treatment groups thereby making comparisons impossible. Although some trials reported adverse cardiac events, the evidence was insufficient to address concerns about the possible risk of cardiotoxicity. We, therefore, cannot justifiably comment on adverse events reported apart from reporting the details.
A U T H O R S ' C O N C L U S I O N S Implications for practice
The six-dose regimen of artemether-lumefantrine is associated with fewer failures and may be a suitable alternative to amodiaquine, amodiaquine plus sulfadoxine-pyrimethamine, and amodiaquine plus artesunate. Available data suggest that mefloquine plus artesunate is as effective and possibly superior to artemether-lumefantrine.
The comparative effectiveness of artemether-lumefantrine was evaluated in a health service setting and the cure rates with unsupervised administration are acceptable.
Implications for research
Trials should be of high quality, with careful attention to concealment of allocation. All participants should be followed up for the duration of the trial regardless of withdrawal from treatment or other protocol violations as this would permit an intentionto-treat analysis. Reasons for all treatment withdrawals should be documented.
Where possible, PCR analysis data should be reported on all treatment failures; if this is not possible, explanations should be given.
Results from different groups should be reported separately.
A C K N O W L E D G E M E N T S
This document is an output from a project funded by the UK Department for International Development (DFID) for the benefit of developing countries. The views expressed are not necessarily those of DFID. 
R E F E R E N C E S
References to studies included in this review
C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Krudsood 2003
Methods Generation of allocation sequence: not described; randomization in ratio 2:1 Allocation concealment: not described Blinding: none Inclusion of all randomized participants in final analysis: 88% (114/130) Participants Number: 130 adults Inclusion criteria: acute uncomplicated falciparum malaria; positive blood slide; weight > 40 kg; age > 14 years; oral intake; agree to hospital admission Exclusion criteria: severe malaria; oral intake not possible; pregnancy or lactation; concomitant disease; taken other antimalarials within past 14 days; urine sulphonamides or 4-aminoquinolones Favours AL Favours DNP
